- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior
An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.
More biosimilars are being launched, but numerous factors affect whether they become available in the clinic. On Monday, July 20, 2020, from 5 to 6 pm EST, MJH Life Sciences™ is hosting a webinar about how biosimilar rebates shape payer policies and provider options.
The program features a panel of leading experts on oncology practice and payment who will provide perspectives on how the structuring of biosimilar payment contracts at the payer level is affecting biosimilar access and cost at the provider level.
With more biosimilars, the expectation is that costs will decline and providers will have more freedom to choose the most appropriate medications for their patients. However, marketplace dynamics have made that ideal a more complicated objective than anticipated.
Providers who want to use biosimilars find their choices of these medicines often are determined not by clinical concerns but by regional payer-by-payer contracts that necessitate careful pharmacy planning, staff training, and sometimes, compromise.
Hear what our panelists have to say about these issues and how they deal with them. They are Kathy W. Oubre, MS, chief operating officer of the Pontchartrain Cancer Center in Louisiana; Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator of Hematology/Oncology for The University of Arizona Cancer Center; and Timothy Chiu, PharmD, BCPS, pharmacist evidence analyst and strategist for Kaiser Permanente.
Click here for registration information.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD
September 7th 2024Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
